Table 2.
Outcomes of ovarian stimulation.
| rFSH-alfa (n=375) |
HP-hMG (n=105) |
uFSH (n=173) |
rFSH-beta (n=118) |
P-value | ||
|---|---|---|---|---|---|---|
| GnRH antagonist protocol | 0.379 | |||||
| Fixed | 278 (74.1) | 85 (81.0) | 124 (71.7) | 87 (73.7) | ||
| Flexible | 97 (25.9) | 20 (19.0) | 49 (28.3) | 31 (26.3) | ||
| Starting dose of Gn (IU) | 150.00 (125.00-200.00) |
200.00 (156.25-225.00) * |
225.00 (225.00-300.00) *† |
175.00 (150.00-200.00) †‡ |
<0.001 | |
| Duration of Gn use (d) | 10.0 (9.0-11.0) | 10.0 (9.0-11.0) * | 10.0 (9.0-11.0) * | 9.0 (9.0-10.0) †‡ | <0.001 | |
| Total Gn dose (IU) | 1500.00 (1275.00-1856.25) |
2137.50 (1750.00-2550.00) * |
2250.00 (1875.00-2775.00) * |
1500.00 (1275.00-1818.75) †‡ |
<0.001 | |
| Trigger day | ||||||
| No. of follicles ≥14mm | 11.5 (9.0-14.0) | 10.0 (8.0-13.0) | 9.0 (7.0-11.0) *† | 11.0 (8.0-13.8) ‡ | <0.001 | |
| E2 (pg/mL) | 5175.50 (3197.30-7630.10) |
3176.30 (2396.35-3988.10) * |
3438.00 (2277.60-5200.30) *† |
4775.05 (3052.38-6981.08) †‡ |
<0.001 | |
| P (ng/mL) | 1.06 (0.77-1.39) | 1.04 (0.79-1.31) | 0.86 (0.66-1.08) * | 1.03 (0.68-1.41) ‡ | <0.001 | |
| LH (IU/L) | 2.20 (1.20-4.10) | 1.65 (1.00-2.75) * | 2.40 (1.60-3.80) † | 2.05 (1.10-3.58) | 0.004 | |
| Single Em thickness (mm) | 5.20 (4.50-6.00) | 5.20 (4.50-5.88) | 5.10 (4.50-6.00) | 5.00 (4.50-5.88) | 0.523 | |
| No. of oocytes retrieved | 17.0 (12.0-21.2) | 11.5 (9.0-15.0) * | 12.0 (9.0-18.0) *† | 16.0 (10.0-21.8) † | <0.001 | |
| No. of MII oocytes | 14.0 (10.0-18.0) | 10.0 (7.2-12.0) * | 12.0 (7.0-16.0) *† | 12.5 (8.0-18.0) † | <0.001 | |
| MII oocyte rate [n(%)] | 5665/6652 (85.2) | 1044/1243 (84.0) | 2144/2582 (83.0) | 1611/1948 (82.7) * | 0.014 | |
| Severe OHSS rate [n(%)] | 12 (3.2) | 0 (0.0) | 1 (0.6) | 3 (2.5) | 0.083 | |
Data are presented as median (25th-75th percentiles) or number (percentage).
*p<0.05 compared to rFSHα group; †p<0.05 compared to HP-hMG group; ‡p<0.05 compared to uFSH group.
GnRH, gonadotropin releasing hormone; LH, luteinizing hormone; E2, estradiol; P, progesterone; Em, endometrium; MII, metaphase II oocytes; OHSS, ovarian hyperstimulation syndrome.